Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Jennifer A. Regan, Yun Cao, Melanie C. Dispenza, Shuo Ma, Leo I. Gordon, Adam M. Petrich*, Bruce S. Bochner

*Corresponding author for this work

Research output: Contribution to journalArticle

14 Scopus citations
Original languageEnglish (US)
Pages (from-to)875-879.e1
JournalJournal of Allergy and Clinical Immunology
Volume140
Issue number3
DOIs
StatePublished - Sep 2017

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this